Use of clinical score to stage and predict outcome of hepatic resection of metastatic colorectal cancer

Journal of Surgical Oncology

Volumn 102, Issue 8, 2010, Pages 914-921

  Feroci, Francesco ^a   Fong, Yuman ^b  

^a MISERICORDIA E DOLCE HOSPITAL   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

clinical risk score; colorectal cancer; hepatic resection; liver metastases; staging system

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER STAGING; COLORECTAL CANCER; HUMAN; LIVER METASTASIS; LIVER RESECTION; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; VALIDATION PROCESS;

COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78650668890     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21715     Document Type: Review

References (62)

1. Rastogi T, Hildesheim A, Sinha R,: Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 2004; 4: 909-917.
2. Geoghegan JG, Scheele J,: Treatment of colorectal liver metastases. Br J Surg 1999; 86: 158-169.
3. Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection. Surgery 1988; 103: 278-288.
4. Scheele J, Stangl R, Altendorf-Hofmann A, et al.: Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110: 13-29.
5. Gayowski TJ, Iwatsuki S, Madariaga JR, et al.: Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery 1994; 116: 703-711.
6. Nordlinger B, Guiguet M, Vaillant JC, et al.: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77: 1254-1262.
7. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946.
8. Ambiru S, Miyazaki M, Isono T, et al.: Hepatic resection for colorectal metastases: Analysis of prognostic factors. Dis Colon Rectum 1999; 42: 632-639. (Pubitemid 29228409)
9. Yamamoto J, Shimada K, Kosuge T, et al.: Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999; 86: 332-337.
10. Minagawa M, Makuuchi M, Torzilli G, et al.: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: Long-term results. Ann Surg 2000; 231: 487-499.
11. Ueno H, Mochizuki H, Hatsuse K, et al.: Indicators for treatment strategies of colorectal liver metastases. Ann Surg 2000; 231: 59-66.
12. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in longterm survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766.
13. Nordlinger B, Van Cutsem E, Rougier P, et al.: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045.
14. Van Cutsem E, Nordlinger B, Adam R, et al.: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221.
15. Poston GJ, Adam R, Alberts S, et al.: Onco-Surge: A strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23: 7125-7134.
16. Younes RN, Rogatko A, Brennan MF,: The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg 1991; 214: 107-113.
17. Cady B, Stone M,: The role of surgical resection of liver metastases in colorectal carcinoma. Semin Oncol 1991; 18: 399-406.
18. Rosen CB, Nagorney DM, Taswell HF, et al.: Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992; 216: 493-504.
19. Jatzko GR, Lisborg PH, Stettner HM, et al.: Hepatic resection for metastases from colorectal carcinoma-A survival analysis. Eur J Cancer 1995; 31A: 41-46.
20. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer, analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-321.
21. Iwatsuki S, Dvorchik I, Madariaga JR, et al.: Hepatic resection for metastatic colorectal adenocarcinoma: A proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-299.
22. Scheele J, Altendorf-Hofmann A, Grube T, et al.: Resektion colorectaler Lebermetastasen,Welche Prognosefaktoren bestimmen die Patientenselektion? Chirurg 2001; 72: 547-560.
23. Schindl M, Wigmore SJ, Currie EJ, et al.: Prognostic scoring in colorectal cancer liver metastases, development and validation. Arch Surg 2005; 140: 183-189.
24. Polk W, Fong Y, Karpeh M, et al.: A technique for the use of cryosurgery to assist hepatic resection. J Am Coll Surg 1995; 180: 171-176.
25. Wittekind CH, Henson DE, Hutter RVP, et al.: editors. UICC. TNM supplement. A commentary on uniform use. 2nd edition. New York: Wiley-Liss, Inc.; 2001.
26. Wittekind CH, Greene FL, Henson DE, et al.: editors. UICC. TNM supplement. A commentary on uniform use. 3rd edition. New York: Wiley-Liss, Inc.; 2003.
27. Lorenz M, Muller HH, Schramm H, et al.: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998; 228: 756-762.
28. Kemeny N, Huang Y, Cohen AM, et al.: Randomized study of hepatic arterial infusion and systemic chemotherapy versus systemic chemotherapy alone as adjuvant treatment following resection of hepatic metastases from colorectal cancer [abstract]. Proceedings of the American Society of Clinical Oncology, Atlanta, GA. 1999; p. 35.
29. Cady B, Stone MD, McDermott WV, Jr., et al.: Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 1992; 127: 561-569.
30. Belluco C, Guillem JG, Kemeny N, et al.: p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996; 14: 2696-2701.
31. Mala T, Bøhler G, Mathisen Ø, et al.: Hepatic resection for colorectal metastases: Can preoperative scoring predict patient outcome? World J Surg 2002; 26: 1348-1353.
32. Mann CD, Metcalfe MS, Leopardi LN, et al.: The clinical risk score: Emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 2004; 139: 1168-1172.
33. Arru M, Aldrighetti L, Castoldi R, et al.: Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg 2008; 32: 93-103.
34. Merkel S, Bialecki D, Meyer T, et al.: Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol 2009; 100: 349-357.
35. Reissfelder C, Rahbari NN, Koch M, et al.: Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 2009; 16: 3279-3288.
36. Rees M, Tekkis PP, Welsh FK, et al.: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann Surg 2008; 247: 125-135.
37. Zakaria S, Donohue JH, Que FG, et al.: Hepatic resection for colorectal metastases: Value for risk scoring systems? Ann Surg 2007; 246: 183-191.
38. Babineau TJ, Lewis WD, Jenkins RL, et al.: Role of staging laparoscopy in the treatment of hepatic malignancy. Am J Surg 1994; 167: 151-154.
39. Rahusen FD, Cuesta MA, Borgstein PJ, et al.: Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. Ann Surg 1999; 230: 31-37.
40. Jarnagin WR, Conlon K, Bodniewicz J, et al.: A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 2001; 91: 1121-1128.
41. John TG, Greig JD, Crosbie JL, et al.: Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann Surg 1994; 220: 711-719.
42. Callery MP, Strasberg SM, Doherty GM, et al.: Staging laparoscopy with laparoscopic ultrasonography: Optimizing resectability in hepatobiliary and pancreatic malignancy. J Am Coll Surg 1997; 185: 33-39.
43. Lo CM, Lai EC, Liu CL, et al.: Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma. Ann Surg 1998; 227: 527-532.
44. Van Dijkum EJ, de Wit LT, van Delden OM, et al.: Staging laparoscopy and laparoscopic ultrasonography in more than 400 patients with upper gastrointestinal carcinoma. J Am Coll Surg 1999; 189: 459-465.
45. Jarnagin WR, Bodniewicz J, Dougherty E, et al.: A prospective analysis of staging laparoscopy in patients with primary and secondary hepatobiliary malignancies. J Gastrointest Surg 2000; 4: 34-43.
46. Weber SM, DeMatteo RP, Fong Y, et al.: Staging laparoscopy in patients with extrahepatic biliary carcinoma: Analysis of 100 patients. Ann Surg 2002; 235: 392-399.
47. D'Angelica M, Fong Y, Weber S, et al.: The role of staging laparoscopy in hepatobiliary malignancy: Prospective analysis of 401 cases. Ann Surg Oncol 2003; 10: 183-189.
48. Reed WP, Mustafa IA,: Laparoscopic screening of surgical candidates with pancreatic cancer or liver tumors. Surg Endosc 1997; 11: 12-14.
49. Grobmyer SR, Fong Y, D'Angelica M, et al.: Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases. Arch Surg 2004; 139: 1326-1330.
50. Mann CD, Neal CP, Metcalfe MS, et al.: Clinical Risk Score predicts yield of staging laparoscopy in patients with colorectal liver metastases. Br J Surg 2007; 94: 855-859.
51. Li Destri G, Di Benedetto F, Torrisi B, et al.: Metachronous liver metastases and resectability: Fong's score and laparoscopic evaluation. HPB (Oxford) 2008; 10: 13-17.
52. Fong Y, Saldinger PF, Akhurst T, et al.: Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178: 282-287.
53. Strasberg SM, Dehdashti F, Siegel BA, et al.: Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study. Ann Surg 2001; 233: 293-299.
54. Schüssler-Fiorenza CM, Mahvi DM, Niederhuber J, et al.: Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg 2004; 8: 150-157; discussion 157-158.
55. Ferrone CR, Kattan MW, Tomlinson JS, et al.: Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 2005; 23: 7529-7535.
56. Shariat SF, Zippe C, Ludecke G, et al.: Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005; 173: 1518-1525.
57. Kattan MW,: Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003; 13: 111-116.
58. Ross PL, Gerigk C, Gonen M, et al.: Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002; 20: 82-88.
59. Rouzier R, Pusztai L, Delaloge S, et al.: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005; 23: 8331-8339.
60. Kattan MW, Gönen M, Jarnagin WR, et al.: A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247: 282-287. (Pubitemid 351156771)
61. Harrell FE, Jr., Califf RM, Pryor DB, et al.: Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546.
62. Eastham JA, Kelly WK, Grossfeld GD, et al.: Cancer and Leukemia Group B (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62: 55-62.